Home > Publications database > Loss of YTHDC1 m6A reading function promotes invasiveness in urothelial carcinoma of the bladder. > print

001     296083
005     20250210113342.0
024 7 _ |a 10.1038/s12276-024-01377-x
|2 doi
024 7 _ |a pmid:39741187
|2 pmid
024 7 _ |a 1226-3613
|2 ISSN
024 7 _ |a 2092-6413
|2 ISSN
037 _ _ |a DKFZ-2025-00031
041 _ _ |a English
082 _ _ |a 540
100 1 _ |a Xu, Jinyun
|0 P:(DE-He78)dd12076e6503be19c4f73ec9bb7793fa
|b 0
|e First author
|u dkfz
245 _ _ |a Loss of YTHDC1 m6A reading function promotes invasiveness in urothelial carcinoma of the bladder.
260 _ _ |a [London]
|c 2025
|b Macmillan Publishers Limited, part of Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1739183578_13025
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a DKFZ-ZMBH Alliance / #EA:A130#LA:A130# / 2025 Feb;57(1):118-130
520 _ _ |a Bladder cancer poses significant clinical challenges due to its high metastatic potential and poor prognosis, especially when it progresses to muscle-invasive stages. Here, we show that the m6A reader YTHDC1 is downregulated in muscle-invasive bladder cancer and is negatively correlated with the expression of epithelial‒mesenchymal transition genes. The functional inhibition or depletion of YTHDC1 increased the migration and invasion of urothelial cells. Integrative analysis of multimodal sequencing datasets provided detailed insights into the molecular mechanisms mediating YTHDC1-dependent phenotypes and identified SMAD6 as a key transcript involved in the invasiveness of urothelial carcinoma of the bladder. Notably, SMAD6 mRNA colocalized less with YTHDC1 in tumoral tissues than in paratumoral tissues, indicating disrupted binding during cancer progression. Our findings establish YTHDC1-dependent m6A reading as a critical epitranscriptomic mechanism regulating bladder cancer invasiveness and provide a paradigm for the epitranscriptomic deregulation of cancer-associated networks.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Koch, Jonas
|0 P:(DE-He78)af92a3d6ca10d83df68e60e15ed7e1ea
|b 1
|u dkfz
700 1 _ |a Schmidt, Claudia
|0 P:(DE-He78)2a599a43bd0b5910c80edb288d8da3e5
|b 2
|u dkfz
700 1 _ |a Nientiedt, Malin
|b 3
700 1 _ |a Neuberger, Manuel
|b 4
700 1 _ |a Erben, Philipp
|b 5
700 1 _ |a Michel, Maurice Stephan
|b 6
700 1 _ |a Rodríguez-Paredes, Manuel
|0 0000-0001-5471-4277
|b 7
700 1 _ |a Lyko, Frank
|0 P:(DE-He78)a8d53a8cdc716390a6cbacdead227143
|b 8
|e Last author
|u dkfz
773 _ _ |a 10.1038/s12276-024-01377-x
|0 PERI:(DE-600)2084833-X
|n 1
|p 118-130
|t Experimental & molecular medicine
|v 57
|y 2025
|x 1226-3613
909 C O |p VDB
|o oai:inrepo02.dkfz.de:296083
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)dd12076e6503be19c4f73ec9bb7793fa
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)af92a3d6ca10d83df68e60e15ed7e1ea
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)2a599a43bd0b5910c80edb288d8da3e5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 0000-0001-5471-4277
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)a8d53a8cdc716390a6cbacdead227143
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EXP MOL MED : 2022
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-05-02T09:05:13Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-05-02T09:05:13Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-05-02T09:05:13Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2023-05-02T09:05:13Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-24
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-24
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b EXP MOL MED : 2022
|d 2023-10-24
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-10-24
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-10-24
920 2 _ |0 I:(DE-He78)A130-20160331
|k A130
|l A130 Epigenetik
|x 0
920 1 _ |0 I:(DE-He78)A130-20160331
|k A130
|l A130 Epigenetik
|x 0
920 1 _ |0 I:(DE-He78)W210-20160331
|k W210
|l Lichtmikroskopie
|x 1
920 0 _ |0 I:(DE-He78)A130-20160331
|k A130
|l A130 Epigenetik
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A130-20160331
980 _ _ |a I:(DE-He78)W210-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21